Extended indication in chronic heart failure authorised by the FDA
News
‘Urgent action needed’ as NHS faces growing waiting lists
A growing number of patients are waiting 52 weeks or more for hospital treatment
EU authorises Celltrion’s adalimumab biosimilar Yuflyma
Yuflyma is approved across 13 indications for the treatment of multiple chronic inflammatory diseases
MHRA launches public consultation on reclassification of two contraceptive pills
Regulatory agency is asking for opinions on reclassifying the pills as pharmacy medications
LifeArc provides £5m funding for COVID-19 genomics study
Study is aiming to understand the role of genetic risk factors in patient responses to COVID-19
AZ, Daiichi Sankyo’s Enhertu scores approval in the UK
Antibody drug conjugate conditionally approved for HER2-positive metastatic breast cancer
Kidney Research UK pledges support to Accelerate@Babraham initiative
Accelerate@Babraham supports early-stage life sciences ventures within the Babraham Research Campus’ community
NICE rejects Lilly’s Verzenios for advanced breast cancer
CDK4 & 6 inhibitor has been available as part of a Cancer Drugs Fund (CDF) managed access agreement
CureVac’s COVID-19 vaccine begins rolling review with EMA
CureVac’s CVnCoV is currently being investigated in a randomised, placebo-controlled Phase IIb/III clinical trial
UK expands COVID-19 vaccinations to over-65s after 15 million receive first dose
People aged 65 to 69 and the clinically vulnerable will be offered the jab from today
Entry deadline extended for INTCR 2021
The entry deadline for the 2021 International Clinical Researcher of the Year has been extended to the 16th of April.
Chiesi launches pilot inhaler recycling scheme in the UK
Scheme will run for 12 months in the Leicester, Leicestershire and Rutland areas
Roche’s vision loss therapy faricimab extends time between treatments by up to four months
Results from four Phase III studies demonstrated non-inferior vision gains with extended dosing schedule
bluebird bio’s beta-thalassaemia gene therapy rejected by NICE
NICE determined that there were uncertainties around the cost-effectiveness of the therapy
NHS to roll-out tocilizumab treatment for COVID-19
In the RECOVERY trial, tocilizumab treatment significantly reduced deaths caused by COVID-19
